Sarah Awan
Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study
Awan, Sarah; Crosby, Vincent; Potter, Vanessa; Hennig, Ivo; Baldwin, David; Ndlovu, Mehluli; Paradine, Sharon; Wilcock, Andrew
Authors
Vincent Crosby
Vanessa Potter
Ivo Hennig
David Baldwin
Mehluli Ndlovu
Sharon Paradine
Andrew Wilcock
Abstract
Clarithromycin may improve cachexia and survival in non-small cell lung cancer (NSCLC), but adequately controlled data are lacking. This study was undertaken primarily to inform the feasibility and scale of a phase III trial. Eligible consenting patients with stage IV NSCLC and cachexia were to be randomized to receive either clarithromycin 250 mg twice daily or placebo for eight weeks. Aspects of trial feasibility recorded included numbers eligible, approached and recruited, together with adherence and completion of treatment and assessments. Over 6 months, none of 125 patients identified fulfilled the entry criteria. The commonest reasons for ineligibility were the use of an excluded concurrent drug (45, 36%), brain metastases (22, 18%), poor performance status (21, 17%) and current chemotherapy (15, 12%). A phase III trial of clarithromycin using these entry criteria is not feasible in this setting. Other macrolides that have a lower risk of a drug–drug interaction may be more practical to pursue.
Citation
Awan, S., Crosby, V., Potter, V., Hennig, I., Baldwin, D., Ndlovu, M., …Wilcock, A. (2017). Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study. Lung Cancer, 104, https://doi.org/10.1016/j.lungcan.2016.12.010
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 18, 2016 |
Online Publication Date | Dec 21, 2016 |
Publication Date | Feb 1, 2017 |
Deposit Date | Nov 20, 2017 |
Publicly Available Date | Nov 20, 2017 |
Journal | Lung Cancer |
Print ISSN | 0169-5002 |
Electronic ISSN | 0169-5002 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 104 |
DOI | https://doi.org/10.1016/j.lungcan.2016.12.010 |
Keywords | Cachexia; Clarithromycin; Macrolide antibiotics; Non-small cell lung cancer |
Public URL | https://nottingham-repository.worktribe.com/output/970565 |
Publisher URL | http://www.sciencedirect.com/science/article/pii/S0169500216305773 |
Files
clarithromycin for cachexia short communication V11_160910_aw.pdf
(271 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0
You might also like
Managing the supportive care needs of those affected by COVID-19
(2020)
Journal Article
A prospective study examining cachexia predictors in patients with incurable cancer
(2019)
Journal Article